Ligand Pharma Inks Deal With Avion To Develop Captisol-enabled Programs

(RTTNews) - Ligand Pharmaceuticals Inc. (LGND) Thursday said it has signed a commercial license agreement with Avion Pharmaceuticals, LLC, for developing and commercializing four Captisol-enabled programs.

As per the agreement, Ligand will receive an up-front payment, revenue from Captisol material sales, potential milestone payments, and royalties from future selling of the products containing Captisol.

John Higgins, President and CEO of Ligand commented: "Ligand continues to expand its portfolio of assets to deliver value to shareholders. Importantly, this partnership also demonstrates new demand for Captisol in both oral and topical administration, adding to the position Captisol has established in enabling injectable products."